Tardive neuroleptic-induced dyskinesias

Close metadata

Drugs that block dopaminergic transmission are currently widely used in the treatment of psychiatric diseases. One of the significant, common complications of therapy are tardive dyskinesias, which develop after prolonged, at least 3 months, therapy with antipsychotics and significantly reduce the quality of life of patients. Tardive dyskinesia is an extrapyramidal disorder, mainly manifested by involuntary hyperkinesis of the muscles of the face and tongue. These movements negatively affect the patient’s daily activities and quality of life. This article reviews the currently available treatment strategies for this type of disorder. One of the promising methods is therapy with Normokinesin (tetrabenazine), which, by reducing dopaminergic stimulation of brain neurons, significantly reduces hyperkinesis.

Keywords:

tardive dyskinesia

neuroleptics

tetrabenazine

Normokineztine

Authors:

Zakharov D.V.

Central City Clinical Hospital;
Jaroslav the Wise Novgorod State University

ORCID: 0000-0001-6884-9949

Buriak Iu.V.

Bekhterev National Medical Research Centerfor Psychiatry and Neurology

Mikhailov V.A.

Received:

29.11.2021

Accepted:

18.12.2021

List of references:

Caroff SN, Campbell EC. Drug-Induced Extrapyramidal Syndromes. Psychiatric Clinics of North America. 2016;39(3):391-411. https://doi.org/10.1016/j.psc.2016.04.003
Zalyalova ZA. Modern classifications of muscular dystonia, treatment strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(3):85-89. (In Russ.).
Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor and Other Hyperkinetic Movements (New York, NY). 2013;3:34-38. https://doi.org/10.7916/D88P5Z71
Boyd KN, Mailman RB. Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs. Handb Exp Pharmacol. 2012;(212):53-86. https://doi.org/10.1007/978-3-642-25761-2_3
Mehta SH, Morgan JC, Sethi KD. Drug-induced Movement Disorders. Neurologic Clinics. 2015;33(1):153-174. https://doi.org/10.1016/j.ncl.2014.09.011
Sethi KD. Movement Disorders Induced by Dopamine Blocking Agents. Seminars in Neurology. 2001;21(01):059-068. https://doi.org/10.1055/s-2001-13120
Witter DP, Holbert RC, Suryadevara U. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opinion on Pharmacotherapy. 2017;18(10):965-972. https://doi.org/10.1080/14656566.2017.1323874
Aosaki T, Miura M, Suzuki T, et al. Acetylcholine-dopamine balance hypothesis in the striatum: An update. Geriatrics & Gerontology International. 2010;10:148-157. https://doi.org/10.1111/j.1447-0594.2010.00588.x
Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use. The Journal of Clinical Psychiatry. 2017;78(3):264-278. https://doi.org/10.4088/JCP.16r10832
Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opinion on Pharmacotherapy. 2016;17(18):2461-2470. https://doi.org/10.1080/14656566.2016.1258063
Caroff SN, Yeomans K, Lenderking WR, et al. RE-KINECT: A Prospective Study of the Presence and Healthcare Burden of Tardive Dyskinesia in Clinical Practice Settings. Journal of Clinical Psychopharmacology. 2020;40(3):259-268. https://doi.org/10.1097/JCP.0000000000001201
Ma HI, Saint-Hilaire M, Thomas CA, et al. Stigma as a key determinant of health-related quality of life in Parkinson’s disease. Quality of Life Research. 2016;25(12):3037-3045. https://doi.org/10.1007/s11136-016-1329-z
Caroff SN, Davis VG, Miller DD, et al. Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. The Journal of Clinical Psychiatry. 2011;72(03):295-303. https://doi.org/10.4088/JCP.09m05793yel
Margolius A, Fernandez HH. Current treatment of tardive dyskinesia. Parkinsonism & Related Disorders. 2019;59:155-160. https://doi.org/10.1016/j.parkreldis.2018.12.022
Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatrica Scandinavica. 1992;86(4):262-266. https://doi.org/10.1111/j.1600-0447.1992.tb03264.x
Gardos G, Casey D, Cole J, Perenyi A. Ten-year outcome of tardive dyskinesia. American Journal of Psychiatry. 1994;151(6):836-841. https://doi.org/10.1176/ajp.151.6.836
Quitkin F, Rifkin A, Gochfeld L. Tardive dyskinesia: are first signs reversible? American Journal of Psychiatry. 1977;134(1):84-87. https://doi.org/10.1176/ajp.134.1.84
Jeste D, Potkin S, Sinha S, et al. Tardive Dyskinesia—Reversible and Persistent. Archives of General Psychiatry. 1979;36(5):585-590. https://doi.org/10.1001/archpsyc.1979.01780050095012
Zutshi D, Cloud LJ, Factor SA. Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic. Tremor and Other Hyperkinetic Movements (New York, NY). 2014;4:266-270. https://doi.org/10.7916/D8MS3R8C
Caroff SN, Mu F, Ayyagari R, et al. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306-310. https://doi.org/10.1186/s12888-018-1889-2
Egan MF, Apud J, Wyatt RJ. Treatment of Tardive Dyskinesia. Schizophrenia Bulletin. 1997;23(4):583-609. https://doi.org/10.1093/schbul/23.4.583
Mentzel CL, Bakker PR, van Os J, et al. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness. The Journal of Clinical Psychiatry. 2017;78(3):279-285. https://doi.org/10.4088/JCP.16m11049
Soares-Weiser K, Fernandez H. Tardive Dyskinesia. Seminars in Neurology. 2007;27(2):159-169. https://doi.org/10.1055/s-2007-971169
Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. The American Journal of Psychiatry. 1973;130(4):479-483.
Bhidayasiri R, Fahn S, Weiner WJ, et al. Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463-469. https://doi.org/10.1212/WNL.0b013e31829d86b6
Mentzel TQ, van der Snoek R, Lieverse R, et al. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia. The Journal of Clinical Psychiatry. 2018;79(6):45-59. https://doi.org/10.4088/JCP.17r11852
Tarsy D, Baldessarini RJ, Tarazi FI. Effects of Newer Antipsychotics on Extrapyramidal Function. CNS Drugs. 2002;16(1):23-45. https://doi.org/10.2165/00023210-200216010-00003
Hyde T, Apud J, Fisher W, Egan M. Drug Induced Movement Disorders. 2nd ed. (Factor S, Lang A, Weiner W, eds.). Malden: Blackwell Publishing; 2005.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences. 2018;389:67-75. https://doi.org/10.1016/j.jns.2018.02.010
El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;12(1):12-19. https://doi.org/10.1002/14651858.CD000458.pub3
Chan CH, Chan HY, Chen YC. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia. International Clinical Psychopharmacology. 2018;33(3):155-162. https://doi.org/10.1097/YIC.0000000000000208
Caroff SN, Campbell EC, Carroll B. Pharmacological treatment of tardive dyskinesia: recent developments. Expert Review of Neurotherapeutics. 2017;17(9):871-881. https://doi.org/10.1080/14737175.2017.1358616
Greil W, Haag H, Rossnagl G, Rüther E. Effect of Anticholinergics on Tardive Dyskinesia. British Journal of Psychiatry. 1984;145(3):304-310. https://doi.org/10.1192/bjp.145.3.304
Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. Neurology and Therapy. 2018;7(2):233-248. https://doi.org/10.1007/s40120-018-0105-0
Pappa S, Tsouli S, Apostolou G, et al. Effects of Amantadine on Tardive Dyskinesia. Clinical Neuropharmacology. 2010;33(6):271-275. https://doi.org/10.1097/WNF.0b013e3181ffde32
Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegenerative Disease Management. 2018;8(2):73-80. https://doi.org/10.2217/nmt-2018-0001
Fedorova NV, Vetokhina VN. Diagnosis And Treatment Of Neuroleptic Extrapyramidal Syndromes. Mental Disorders in General Medicine. 2009;3:18-24. (In Russ.).
Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry. 1993;34(10):713-738. https://doi.org/10.1016/0006-3223(93)90044-E
Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;2018(3):CD000207 . https://doi.org/10.1002/14651858.CD000207.pub2
Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;2018(1). https://doi.org/10.1002/14651858.CD000205.pub3
Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews. 2018;2018(4). https://doi.org/10.1002/14651858.CD000203.pub4
Zakharov DV, Mikhailov VA, Hublarova LA, Zalyalova ZA. Treatment of tardive neuroleptic dyskinesia. Review of Psychiatry and Medical Psychology n.a. V.M. Bekhterev. 2014;3:129-131. (In Russ.).
Pletscher A. Release of 5-Hydroxytryptamine by Benzoquinolizine Derivatives with Sedative Action. Science. 1957;126(3272):507-507. https://doi.org/10.1126/science.126.3272.507
Kaur N, Kumar P, Jamwal S, Deshmukh R, Gauttam V. Tetrabenazine: Spotlight on Drug Review. Annals of Neurosciences. 2016;23(3):176-185. https://doi.org/10.1159/000449184
Eiden EL. The vesicular neurotransmitter transporters: current perspectives and future prospects. The FASEB Journal. 2000;14(15):2396-2400. https://doi.org/10.1096/fj.00-0817rev
Eiden LE, Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Annals of the New York Academy of Sciences. 2011;1216(1):86-98. https://doi.org/10.1111/j.1749-6632.2010.05906.x
Caroff SN, Aggarwal S, Yonan C. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Journal of Comparative Effectiveness Research. 2018;7(2):135-148. https://doi.org/10.2217/cer-2017-0065
Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Review of Neurotherapeutics. 2018;18(4):323-332. https://doi.org/10.1080/14737175.2018.1455504
Solmi M, Pigato G, Kane JM, Correll C. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy. 2018;Volume 12:1215-1238. https://doi.org/10.2147/DDDT.S133205
Leung JG, Breden EL. Tetrabenazine for the Treatment of Tardive Dyskinesia. Annals of Pharmacotherapy. 2011;45(4):525-531. https://doi.org/10.1345/aph.1P312
Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358-362. https://doi.org/10.1212/WNL.48.2.358
Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic disorders. Movement Disorders. 2007;22(2):193-197. https://doi.org/10.1002/mds.21222
Miguel R, Mendonça MD, Barbosa R, et al. Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Therapeutic Advances in Neurological Disorders. 2017;10(2):81-90. https://doi.org/10.1177/1756285616677004
Factor S, Hauser R, Mandri D, et al. A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2 (S27.007). Neurology. 2016;86(16 suppl):27.007.

Close metadata